Early Menopause and Primary Ovarian Insufficiency

The single most consequential misunderstanding about this condition is that it is menopause arriving early, and should therefore be treated like menopause. It is not, and it should not be.

What it is, and what it is called

Primary ovarian insufficiency is loss of ovarian function indicated by irregular menstrual cycles together with biochemical confirmation, before the age of 40. The older name, premature ovarian failure, has largely been abandoned. ACOG describes the condition as a spectrum of declining ovarian function rather than an absolute end point, which is part of why the contraception question below is not straightforward.

Recent data indicate a prevalence of 3.5%, higher than was previously thought. At least 90% of cases are idiopathic — no cause is found. Among the identifiable causes are conditions affecting the X chromosome, including Turner syndrome and its mosaic forms, isochromosome X, and FMR1 premutation carriers. Diagnostic delay is common.

Why the treatment is different from menopause treatment

This is the point to carry away. For a woman at the usual age of menopause, hormone therapy relieves symptoms and also prevents bone loss and fracture — the 2022 position statement of The North American Menopause Society describes it as “the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause” and states that it “has been shown to prevent bone loss and fracture.” Before 40, the objective is different in kind: to replace hormones the ovary would still be producing — ACOG describes this as distinctly different from hormonal therapy for menopause, with goals extending beyond symptom relief to levels that support bone, cardiovascular and sexual health.

Two consequences follow. Young women with the condition may need higher doses of estrogen than menopausal women to achieve adequate replacement and optimal bone health. And treatment should continue until the average age of natural menopause is reached, around 50 to 51 — not for a few years, and not until symptoms settle.

Hormone therapy here is indicated to reduce the risk of osteoporosis, cardiovascular disease and urogenital atrophy, and to improve quality of life. Either oral or transdermal delivery achieving replacement levels of estrogen is recommended as first-line. Data comparing specific regimens in this population are lacking, which is worth knowing when a clinician cannot give you a definitive answer about which preparation is best — that uncertainty is real rather than evasive.

The contraception paradox

Two facts sit uncomfortably together, and both matter.

Spontaneous pregnancy remains possible, though the odds are modest. And hormone therapy at replacement doses does not reliably prevent pregnancy — combined hormonal contraceptives prevent ovulation and pregnancy more reliably than hormone therapy does. So if pregnancy prevention is a priority for you, that is a specific conversation to have rather than an assumption to make in either direction. Being told you are unlikely to conceive is not the same as being protected.

Why cardiovascular risk is part of this

Earlier loss of ovarian function is associated with greater cardiovascular risk, and the relationship is graded rather than binary. In a 20-year follow-up of a Netherlands cohort of around 12,000 women, cardiovascular mortality decreased by 2% for every year that menopause was delayed after age 39. In a prospective study following more than 6,000 US women for 12 years, those reporting menopause between 35 and 40 had a 50% greater subsequent risk of ischaemic heart disease-related outcomes.

This is a large part of why hormone therapy is framed as risk reduction here rather than as symptom control, and why stopping it early is a decision with consequences beyond how you feel.

What a full assessment covers

The 2024 evidence-based guideline on premature ovarian insufficiency addresses 40 clinical questions across bone, cardiovascular, neurological and sexual function, fertility and general wellbeing, with 145 recommendations. That breadth is itself informative: adequate care is not a prescription and a follow-up in a year.

Bone density assessment has a place, though the guideline notes that the value of repeated DXA monitoring in women with normal bone density remains uncertain. The guideline’s scope is itself the useful signal here: it treats fertility, psychological health and general wellbeing as domains requiring their own assessment and management, not as consequences to be absorbed. If your care has covered hormone therapy and nothing else, that is a gap worth naming at the next appointment.

What to raise at a visit

• Whether your diagnosis was confirmed biochemically, and when
• Whether hormone therapy is at replacement levels rather than a menopause dose
• The plan for continuing treatment to around age 51, and what would prompt changing it
• Contraception, if pregnancy is not currently wanted — explicitly, given the paradox above
• Bone density assessment, cardiovascular risk factors, and when each is reviewed
• Fertility counselling, and mental health support

Main takeaway

This is replacement, not menopause treatment. Doses may need to be higher than a menopausal woman’s, and treatment continues to roughly age 50 to 51 to reduce the risks of osteoporosis and cardiovascular disease rather than only to control symptoms. Hormone therapy does not reliably prevent pregnancy and spontaneous conception remains possible, so contraception is a separate conversation.